KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Enterprise Value (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Enterprise Value for 17 consecutive years, with -$10.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 1.54% to -$10.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.6 billion, a 1.54% increase, with the full-year FY2025 number at -$10.6 billion, up 1.54% from a year prior.
  • Enterprise Value was -$10.6 billion for Q4 2025 at Bristol Myers Squibb, up from -$15.7 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$6.2 billion in Q2 2024 to a low of -$16.9 billion in Q4 2021.
  • A 5-year average of -$11.3 billion and a median of -$10.8 billion in 2024 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 50.8% in 2022, then tumbled 117.17% in 2025.
  • Bristol Myers Squibb's Enterprise Value stood at -$16.9 billion in 2021, then surged by 45.61% to -$9.2 billion in 2022, then plummeted by 32.94% to -$12.2 billion in 2023, then rose by 11.61% to -$10.8 billion in 2024, then rose by 1.54% to -$10.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Enterprise Value are -$10.6 billion (Q4 2025), -$15.7 billion (Q3 2025), and -$13.5 billion (Q2 2025).